I. Introduction
In the past 25 years or so, no disease has endangered and taken away as many lives of human beings and their resources as AIDS. AIDS is, in fact, rewriting medical history as humankind's deadliest scourge. HIV/AIDS is the fourth leading cause of death worldwide, killing more than 2.1 million people in 2007. This condition progressively reduces the effectiveness of the immune system and leaves individuals susceptible to life threatening opportunistic infections, neurological disorders or certain unusual malignancies.
The AIDS Epidemic, since its discovery in 1981, is spreading all over the world breaking all social, cultural and geographical barriers. In 2007, it was estimated by WHO that 33.2 million people lived infected with the HIV virus worldwide. [1] In the absence of antiretroviral therapy, the median time of progression from HIV infection to AIDS is nine to ten years, and the median survival time after developing AIDS is only 9.2 months. [2] Although treatments for AIDS and HIV can slow the course of the disease, there is currently no vaccine or cure. Current treatment for HIV infection consists of "highly active antiretroviral therapy", or HAART introduced in 1996. [3] Current optimal HAART regimens consist of combinations of at least three drugs belonging to at least two classes of antiretroviral agents, typically of two nucleoside reverse transcriptase inhibitors (NRTIs) plus either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor (NNRTI). The main parameters to recommend initiating treatment are viral load, rapidity in CD4 decline, and patient readiness. [4] The goal of antiretroviral therapy is to maximally and durably inhibit viral replication so that the patient can attain and maintain effective immune response towards potential microbial pathogens so that there is improvement in the patient"s quality of life, reduction in complications, and reduction of HIV viremia below the limit of detection. Many HIV-infected individuals have experienced remarkable improvements in their general health and quality of life, which has led to the plummeting of HIV-associated morbidity and mortality. [5] Although access and efficacy of first line therapy is reasonably well-established, there is a substantial and unacceptable mortality rate in the first six months after initiation of antiretroviral therapy, particularly in those with low CD4 cell counts and late stage disease. Failure of first line therapy is inevitable in a proportion of patients due to the likely emergence of high-level resistance during first line therapy. Many studies to date have confirmed the use of second line regimens when HIV RNA assay show virological failure of first line therapy.
The goal of second line therapy is to retard clinical progression of the disease rather than complete suppression of viraemia. The time of switching is dictated by treatment failure, and this can be measured in three ways: clinically, by disease progression and WHO staging; immunologically, using trends in CD4 counts over time, and virologically, by measuring HIV viral loads (plasma HIV-1 RNA levels).
The new second-line regimen has to involve drugs that retain activity against the patient"s virus strain and should ideally include a minimum of three active drugs, one of them drawn from at least one new class, in order to increase the likelihood of treatment success and minimize the risk of cross-resistance. The basic principle is ideally to support the chosen boosted PI with a dual NRTI backbone composed of two unused NRTIs. [6] The data regarding various aspects of second line antiretroviral therapy is sparse due to nonavailability, cost and complexities of second line regimen in a resource-limited country like India and hence, this study was undertaken.
Treatment
There is no specific treatment either for HIV infection or the immunodeficiency caused by it. Palliative treatment of the symptoms and cure of the opportunistic infections were the only options available. Now various categories of Anti-Retro Viral drugs (ARVs) are available. These drugs can only contain the infection but not cure the disease.
Antiretroviral agents are drugs which act at various stages of the life cycle of HIV in the body and work by interrupting the process of viral replication. Theoretically, ARV drugs can act in any of the following ways during different stages of viral replication [11] .  Block viral RNA cleavage and inhibit the enzyme reverse transcriptase (reverse transcriptase inhibitors)  Block the enzyme, integrase, which helps in the incorporation of the proviral DNA into the host cell chromosome (integrase inhibitors)  Block the RNA so as to prevent viral protein production.  Block the enzyme protease (protease inhibitors)  Inhibit the budding of virus from host cells.  Block binding of HIV to target cell (fusion inhibitors)
The currently available agents target the virus mainly by inhibiting the enzymes reverse transcriptase (RT inhibitors) and protease (protease inhibitors), and thus prevent fusion of the virus with CD4 cells (fusion inhibitors).
Classes of ART drugs available
When several such drugs, typically three or four, are taken in combination, the approach is known as highly active antiretroviral therapy, or HAART. It is done to prevent developing resistance to antiretroviral drugs.
Viral load and CD4 cell count Viral load and CD4 cell tests provide critical information for decisions on antiretroviral therapy (ART). Viral load should be tested: [12]  Before starting or changing medications. This provides a reference value;  About 2 to 8 weeks after starting or changing medications. This shows whether the new drugs are working;  Every 3 or 4 months. This helps make sure the medications are still working. For patients who haven"t started taking medications, it helps decide when to start. The national programme in India does not recommend routine viral load monitoring. Viral load measurement is not recommended for decision-making for the initiation or regular monitoring of ART in resource-limited settings [6] . CD4 cell counts should be done: [12]  When someone first tests HIV-positive  every three to four months to (1) determine when to start antiretroviral therapy in patients not being treated;
(2) assess immunologic response to antiretroviral therapy; and (3) assess the need for initiation or discontinuation of prophylaxis for opportunistic infections. 
Goals of therapy
The currently available ARV drugs cannot eradicate the HIV infection from the human body. This is because a pool of latently infected CD 4 cells is established during the earliest stages of acute HIV infection and persists within the organs/cells and fluids (e.g., liver and lymphoid tissue) even with prolonged suppression of plasma viraemia to <50 copies/ml by antiretroviral therapy. The goals of therapy are as follows: [10] Adverse effects of the ART drugs Antiretroviral therapy can have a wide range of adverse effects on the human body. Common but mild adverse effects occurring early in most antiretroviral regimens include gastrointestinal effects such as bloating, nausea and diarrhea, which may be transient or may persist throughout therapy. Other common nuisance adverse effects are fatigue and headache caused by AZT and nightmares associated with EFV. Several uncommon but more serious adverse effects associated with antiretroviral therapy, including AZT-associated anemia, d4T-associated peripheral neuropathy, PI-associated retinoid toxicity and NNRTI-associated hypersensitivity reactions. These side effects are treated according to accepted therapy for these conditions in patients not receiving HAART. The adverse effects are [13]  Gastrointestinal -abdominal pain, diarrhoea, nausea, vomiting, flatulence, hepatitis, hyperbilirubinemia, hypercholesterolemia, liver failure, alteration in taste,  Central Nervous System related -dizziness, headache, insomnia, mental confusion, migraines, mood swings, nightmares, numbness, somnolence  General -Steven-Johnson syndrome, xeroderma (dry skin), xerostomia (dry mouth), alopecia, anemia, hyperpigmentation, ingrown nails, lipodystrophy, malaise, myalgia, myopathy, neutropenia, aphthous ulcers, rash, renal failure
Resistance to antiretroviral therapy
When HIV multiplies, most of the new copies are mutated i.e. they are slightly different from the original virus. Some mutations keep multiplying even when the patient is taking antiretroviral drugs. When this happens, the drug will stop working. This is called "developing resistance" to the drug.
If only one ARV drug is used, it is easy for the virus to develop resistance. For this reason, using just one ARV drug (monotherapy) is not recommended. But if two drugs are used, a successful mutant would have to get around both drugs at the same time. And if three drugs are used, it"s very hard for the right mutations to show up that can resist all three drugs at the same time. Using a triple-drug combination means it takes much longer for resistance to develop.
Viral resistance testing helps health care providers choose the most effective drugs. Resistance testing is recommended for patients starting therapy, when viral load is not controlled by new medications, or when it "breaks through" a regimen that used to work. The guidelines recommend resistance testing before starting antiretroviral treatment (ART). It can also make sense for people who don"t need to start ART yet. This can show if the person got infected with drug-resistant virus.
Reasons for switch to second line therapy Antiretroviral treatment failure can be defined as a suboptimal response to therapy.
Virological failure:
 Within 6 months after starting a treatment, the viral load should drop below 400 copies. Within 1 year, it should be less than 50 copies. If the viral load does not drop this much, change the treatment.  An increase in viral load from undetectable to detectable levels  Plasma viral load > 10,000 copies/mL
Immunological failure
 Fall of CD4 count to pre-therapy baseline (or below)  50% fall from the on-treatment peak value (if known)  Persistent CD4 levels below 100 cells/mm Clinical failure  New or recurrent WHO stage 4 condition, after at least 6 months of ART, with some exceptions like lymph node TB, uncomplicated TB pleural disease, oesophageal candidiasis, recurrent bacterial pneumonia which may not indicate treatment failure.
Second line ART
Second-line ART is the next regimen used in sequence immediately after first-line therapy has failed (clinically, and or immunologically and or virologically). Current WHO treatment guidelines recommend that the protease inhibitor (PI) class should be reserved for second-line ART and that Ritonavir-boosted protease inhibitors (bPIs) are preferred supported by two agents from the NRTI class. Humphreys et al from University of California found that there is insufficient evidence to evaluate second line therapies in patients who fail first line treatment. [ Methodology 30 patients on second line antiretroviral Therapy attending the antiretroviral treatment clinic of a tertiary care hospital were included in the study. 1. Patients were dealt with individually in the examination room. 2. Informed consent was obtained from the patients before conducting the study using the form attached in appendix-A. 3. Demographic profile of patients such as name, age, sex, residence and socioeconomic status were noted. 4. Structured pro forma and in-depth interviews with the patients were conducted. 5. Onset and duration of HIV infection were noted. 6. Indication for which patient had been initiated on first line Anti-retroviral Therapy was noted. 7. Detailed clinical features including height, weight, vital parameters, any past or concomitant opportunistic infection were noted from the patients" clinical record. The functional status of the patient whether working, ambulatory or bedridden was noted. 8. The major body systems like central nervous, cardiovascular, respiratory, gastrointestinal were clinically examined thoroughly for any abnormality. 9. Detailed laboratory profile was recorded as under 
Data analysis
The questionnaires were checked for completeness and the data was compiled on computer using MS EXCEL programme.
III. Observations And Results

Demographic profile of the patients
A total of 30 patients who were on second-line antiretroviral therapy and met the inclusion criteria were considered for the present study, after obtaining their informed consent. The socio-demographic profile of the respondents was as follows: Age: The mean age of the patients was 40.33 years with standard deviation of 6.26 years with a range of 32 to 53 years. The distribution of patients according to age has been shown in table 1. Table 1 . Distribution of age groups of patients Gender: Out of 30 patients undertaken for study, 23(76.67%) were male and 7(23.33%) were female as shown in fig. 1 .
Fig 1. Distribution of patients according to gender
Socioeconomic status: 24(80.00%) patients were in the lower-middle class, 4(13.33%) were in the uppermiddle class and 2(6.67%) of the patients were in the upper-lower class according to Kuppuswamy"s scale of socioeconomic classification [17] . The distribution has been shown in table 2. Lymphadenopathy: 28(93.33%) patients in the study had no lymph node enlargement. 1(3.33%) patient had cervical and abdominal lymphadenopathy and 1(3.33%) patient had axillary lymphadenopathy, which has been depicted in fig 3. 
Fig 3. Lymphadenopathy
Opportunistic Infections: 10(33.33%) patients had not developed any opportunistic infections till the time of study. 2(6.67%) patient had developed Cryptococcal meningitis. 12(40%) patients had developed Tuberculosis in the course of their illness. 4(13.33%) had developed Cytomegalovirus infection, 2(6.67%) patient suffered from Pneumocystis carinii Pneumonia, 1(3.33%) from Cryptosporidium infection, 2(6.67%) from diarrhoea and 3(9.09%) from Herpes Zoster infection. Six patients had more than one opportunistic infections. This has been shown in fig 
CD8 Cell Count:
The mean CD8 cell count of the patients was 814/mm3 with standard deviation of 622/mm3 with a range of 102/mm3 to >2000/mm3. 3 patients had CD8 cell count >2000/mm3, 22 patients had CD8 cell count between 501-2000/mm3 and 5 patients had CD8 cell count less than 500/mm3. The details have been shown in Fig 11 . Reason for switch to second line therapy: 19(63.33%) patients had been switched to second line therapy due to immunological failure, 8(26.67%) patients had been switched to second line therapy due to clinical treatment failure, 2(6.67%) patients had been switched due to both immunological and clinical treatment failure and 1(3.33%) patient had been transferred to second line therapy due to both immunological and virological failure. The details are shown in fig 14.   Fig 14. Reason for switch to second line therapy Details of second line therapy: On switching to second line antiretroviral therapy, the drug regimens followed were as under in table 7: Other drugs e.g. Antitubercular Therapy (ATT) or antimicrobials for prophylaxis against infections and multivitamins were continued as per schedule,as shown in table Adverse effects of second line drugs: 13 patients did not experience any side-effect of antiretroviral drugs. 10 patients experienced side-effects pertaining to central nervous system like headache, dizziness, memory loss and delusions etc. 2 patients developed loose motions, 1 patient developed numbness in his left arm, 1 patient had generalised pruritus and 1 patient had weight loss and anorexia due to therapy. 1 patient had burning sensation during urination and 1 patient developed diminution of vision. The adverse effects experienced by patients have been shown in table 8. 
Details of Therapy
IV. Discussion
General In our study, 30 patients were included. Mean age of patients was 40.33 years. Except for 6.67% of patients, who were in upper middle strata, others had relatively lower socioeconomic status including 13.33% who were in lower middle strata. The patients were thus similar in general demographic profile.
The distribution of patients according to gender revealed that only 23.33% of patients under study were female, thus reflecting low access of females to antiretroviral care due to social, economic and cultural disparities in the society, specifically they had poor access to HIV care and treatment due to poor literacy, lack of transportation, social stigma attached with HIV-infected female and lack of awareness about the disease.
Clinical, Immunological and Virological Profile
Mean duration of illness of patients was 6 years, but 33.33% patients had been infected with HIV since 6-14 years, thus showing reduced mortality after second line antiretroviral therapy.
Only 6.67% patients had body mass index (BMI) less than 17, with no patient in the overweight category. Majority of patients had BMI in the normal range (18.50-24.99).
An overwhelming majority (93.33%) of patients did not have any lymph node enlargement. However one patient had both cervical and abdominal lymphadenopathy and one patient had enlarged axillary lymph nodes.
66.67% of patients had been attacked with opportunistic infections. Tuberculosis was the commonest opportunistic infection, accounting for 60% of all opportunistic infections. Six patients had more than one opportunistic infections, validating that opportunistic infections in HIV patients, reduce the immunity further.
Majority of patients (86.67%) were in stage 3 and stage 4 of HIV, according to WHO clinical staging of HIV/AIDS, thus indicating the need to administer second line treatment. Staging is a useful approach in studies of progression to symptomatic HIV disease in resource-limited setting.
None of the patients was bedridden. Only 16.67% of patients were ambulatory but not in full functional capacity and majority (83.33%) in working condition. This points towards improvement in functional status and quality of life due to therapy.
On clinical examination of various body systems, most of the patients were found to be normal. 6 patients had signs of peripheral neuropathy and 5 patients had liver enlargement of varying degree, which might be due to drug toxicity. This is because of excellent functional and clinical recovery that occurs on institution of ART along with prompt and comprehensive treatment of opportunistic infections.
Laboratory findings of the patients revealed that 16.67% of patients had hemoglobin concentration <11 g/dl.
Mean CD4 cell count increased from 114/mm3 at start of first line therapy to 168/mm3 at start of second line therapy. This indicates late induction of first line therapy but early detection of first line failure by CD4 cell count.
Viral load was estimated in only 50% of cases due to high cost of investigations and lack of access to specialized laboratory services. At the time of starting second line therapy, out of 15 patients in whom viral load was estimated, 11 had done >20,000 copies of HIV virus/ml.
A sizeable number (83.33%) of patients were started on first line antiretroviral therapy due to low CD4 cell count, irrespective of their symptomatic status. It suggests that there was delay and inaccessibility to approach antiretroviral care, till the immunodeficiency became too severe, since the patients were unaware of the infection as is the usual scenario in India.
The first line regimen for antiretroviral treatment consisted of 2 NRTIs and 1 NNRTI in all 30 patients, which is the preferred first line regimen according to WHO and National AIDS Control Organization guidelines.
HIV viral resistance testing was done in only 7 patients. In Western countries viral resistance testing is done prior to initiation of first line therapy. However in a resource-limited setting like India, due to expense, non-availability and inaccessibility of viral resistance testing, it is done only in selected patients. The resistance of these patients revealed that majority of patients (64.28%) were resistant to NRTI as they form the initial backbone ART in India, due to easy availability, low pill burden and having relatively low toxicity.
Switch to second line regimen was made in all 30 patients due to failure of first line regimen. In the present study, 63.33% patients had been switched due to immunological failure and 26.67% had clinical treatment failure as the reason. 2 patients had both immunological and clinical failure and only one patient was switched to second line regimen due to immunological and virological failure.
Normally virological failure is the earliest and most accurate to detect by HIV RNA assay, followed by immunological failure and lastly by clinical treatment failure, as manifested. However in a developing country like India, due to high cost, ignorance, inaccessibility and non-availability of antiretroviral care, in general settings, clinical failure is detected first followed by CD4 count and lastly the virological failure by HIV RNA assay. But with widespread availability of CD4 cell count estimation by National AIDS Control Organization (NACO) affiliated centers and Antiretroviral Centers of the medical colleges CD4 cell count is being increasingly used to determine the immunological failure, which is being taken as the major criteria for switching to second line therapy. This is reflected in this study also, where majority (63.33%) of patients have been started on second line therapy due to immunological failure. In few cases where viral load was estimated, 1 patient was switched to second line therapy due to both immunological and virological failure. Possible reasons of first line treatment failure might be:  Incomplete adherence  Intolerance to therapy due to adverse effects  Pharmacokinetic issues like Poor understanding of the details of the medication regimen  Failure to access antiretroviral care  Low literacy level  Since in India, viral resistance testing is not done before the initiation of first line regimen due to nonavailability, inaccessibility and high expense, possibly in few patients HIV virus might not have been susceptible to the drugs administered in the first line therapy itself.
On switching to second line antiretroviral therapy, the most common drug regimen followed was Tenofovir + Abacavir + Lopinavir + Ritonavir, in 73.33% of patients, in accordance with the viral resistance testing studies, good outcomes, low toxicity and high compliance. 3 patients were administered Zidovudine + Lamivudine + Saquinavir + Ritonavir. 2 patients were prescribed the regimen Tenofovir + Abacavir + Efavirenz.
The various adverse effects experienced by majority (56.67%) of patients. Most of the adverse effects were central nervous system related like headache, dizziness, delusions etc. experienced by 10 (33.33%) patients. 2 patients complained of loose motions due to drugs. Other adverse effects experienced were numbness, pruritus, burning sensation during urination, weight loss and diminution of vision, each complained by 1 patient. In comparison with first line antiretroviral therapy, the second line regimens are more complex due to high pill burden and large number of drug interactions. We did not encounter significant metabolic abnormalities like hyperglycemia, dyslipidemia as the mean duration of second line ART was too small.
V. Conclusion
 Second line antiretroviral therapy has changed the prognosis of HIV infected patients who have first line regimen failure.  There was delay and inaccessibility in starting antiretroviral therapy due to ignorance, high cost and nonavailability. Access to second line ART regimens is relatively limited in developing countries like India.  The switch to second line treatment was relatively slow, due to CD4 cell count being used as the main criteria to switch therapy. Viral load was done in only selected cases due to high cost, inaccessibility, nonavailability of required laboratory services. This study highlights the importance of assessing viral load to monitor any early virological failure in patients on first line ART to switch early to second line therapy. Until viral load testing is widely available, cheap and done regularly, it would not be possible to detect first line ART failure early. Till then, CD4 cell count should be used as a guiding factor to detect early first line ART failure.  The most common second line regimen followed by patients is Tenofovir + Abacavir + Lopinavir + Ritonavir, but it shows a high incidence of minor adverse effects. The response to therapy was good in terms of clinical and immunological parameters.  Viral Resistance testing revealed resistance to NRTI in 64.28% and NNRTI in 42.85% and PI in 14.28% cases.
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